Colgate-Palmolive Company

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

Colgate-Palmolive (CL): Can Hill’s Turn Premium Pricing Into Better Profits?

Company update Premium pricing AI-generated analysis

πŸ“Š Colgate-Palmolive trades at a forward P/E of 22x, reflecting a valuation between its 2024 and 2025 historical levels as earnings outlook improves but remains below peak growth rates.

🦴 The company holds a 41.3% global toothpaste market share by value through Q2 2026, supported by familiar brands and broad distribution networks that drive recurring sales.

🐾 Hill's pet nutrition is transitioning from private-label exit to branded nutrition to capture higher margins, with Prescription Diet showing both pricing and volume growth in the second quarter.

πŸ’° Reported GAAP profit was depressed by a $919 million pretax skin-health impairment in 2025, though management expects mid-single-digit Base Business EPS growth in 2026 excluding such charges.

πŸ“‰ Organic sales grew 7.4% in 2024 but slowed to 1.4% in 2025 due to category demand weakness and material cost pressures, necessitating a recovery in volume to spread factory costs.

πŸ“ˆ Second-quarter organic sales rose 2.1% with pricing up 3.9%, though volume declined 1.8%; management notes volume would have been flat without the private-label exit.

πŸ› οΈ The restructuring program carries estimated cumulative pretax charges of $350 million to $550 million, with 80-90% requiring cash, substantially all expected by the end of 2028.

πŸ“‰ Operating margin declined to 22.5% from 22.9% in Q2 due to a 2.6 point rise in selling and administrative expenses, predominantly driven by increased advertising spend.

πŸ’΅ First-half operating cash flow generated $1.742 billion, with capital expenditures of $266 million leaving approximately $1.48 billion, which was largely consumed by dividends and repurchases.

πŸ† Colgate-Palmolive is included in Insider Monkey's list of 10 Best Dividend Kings To Buy According to Hedge Funds, highlighting its status as a reliable income stock.

Bullish Signals
  • Colgate-Palmolive holds a dominant 41.3% global toothpaste market share by value through Q2 2026, supported by durable franchises and broad distribution.
  • Hill's Prescription Diet delivered both pricing and volume growth in the second quarter, demonstrating that therapeutic demand can withstand higher prices.
  • Management expects mid-single-digit Base Business EPS growth in 2026, supported by pricing power and productivity gains despite higher input costs.
  • Second-quarter adjusted net income increased 6%, while EPS rose 8% as fewer shares divided the profit due to share buybacks.
  • Hill's gross margin improved 2.4 percentage points through productivity, pricing, and mix adjustments in the second quarter.
  • The company generated $1.742 billion of first-half operating cash, with net cash retained after distributions increasing from $1.25 billion to about $1.48 billion.
Risk Factors
  • Reported GAAP profit was depressed by a $919 million pretax skin-health impairment recorded in 2025 after business prospects weakened, particularly in China.
  • Organic sales growth slowed to 1.4% in 2025 from 7.4% in 2024 as category demand weakened and material costs pressured margins.
  • Operating margin declined to 22.5% from 22.9% in Q2 due to a 2.6 point rise in selling and administrative expenses, predominantly because of increased advertising.
  • The restructuring program carries estimated cumulative pretax charges of $350 million to $550 million, with 80-90% requiring cash payments.
  • Working-capital movements absorbed $137 million less cash than a year earlier, as improved payables and other movements outweighed additional money tied up in inventories.
  • Sustaining the current valuation requires sales to outgrow advertising and overhead so that better manufacturing economics reach shareholders.
Full Analysis
Colgate-Palmolive (CL) is evaluated as fairly valued with a forward P/E of 22x, supported by durable franchises in oral care and pet nutrition which accounted for roughly two-thirds of 2025 revenue. The company reported a 41.3% global toothpaste market share by value through Q2 2026, leveraging scale to protect margins despite higher input costs and advertising expenses. A key strategic focus is the transition within its Hill's pet nutrition division, which is replacing private-label production with branded nutrition to improve per-unit profitability. While therapeutic nutrition segments like Prescription Diet showed pricing and volume growth in Q2 2026, management faces the challenge of sustaining this momentum against broader category slowdowns and rising marketing costs. Financial performance was impacted by a $919 million pretax skin-health impairment recorded in 2025, primarily due to weakened prospects in China. Excluding this charge, Base Business EPS is expected to grow in the mid-single digits in 2026, driven by pricing power and productivity gains that offset inflation and restructuring charges totaling an estimated $350 million to $550 million. Analysts project roughly 6% adjusted EPS growth for 2027, though sustaining the current valuation requires organic sales to outpace advertising spend and overhead. The investment case hinges on Hill's ability to broaden branded volume growth and generate cash flow that supports distributions without requiring additional borrowing or dilution.